Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25840123 | 0.86 | PRMT3 (0.34) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL25826457 | 0.81 | PRMT3 (0.35) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL25823202 | 0.76 | PIK3CD (0.36) | — | |
| SCHEMBL254237 | 0.72 | — | — | |
| SCHEMBL13655843 | 0.71 | PRMT3 (0.32) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| Hydrochloric Acid SCHEMBL21816614 | 0.70 | — | — | |
| SCHEMBL29074467 | 0.68 | PRMT1 (0.50) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL4270520 | 0.68 | PRMT1 (0.50) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL8717205 | 0.68 | PRMT1 (0.50) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL18950460 | 0.68 | PRMT1 (0.50) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | PRMT3 917/4885CARM1 3002/4885PRMT6 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.